ADA/EASD Guidelines Back T2D Screening for Hypercortisolism, Citing Corcept's Mifepristone Data
CORT has more than doubled off its 52-week low of $28.66 on light trading volume (0.4× avg).
Summary
The 2026 ADA/EASD Type 2 Diabetes consensus report now recommends screening hard-to-control T2D patients for hypercortisolism and cites Corcept's CATALYST trial, where mifepristone cut HbA1c by 1.47% versus 0.15% on placebo over 24 weeks. Roughly 24% of screened refractory T2D patients had hypercortisolism, a prevalence figure that supports a meaningfully larger addressable pool for Korlym beyond classic Cushing's. Guideline recognition is the kind of endorsement that can push insurers toward coverage and get endocrinologists to order the test. This lands as Corcept's core franchise faces generic pressure and the company leans on its Lifyorli oncology launch, which drove Q2 revenue up 32% to $256.1M. The real test is implementation: screening has to happen at scale and Korlym prescriptions have to show measurable uptake before this translates into revenue.
At the time of this announcement, CORT was trading at $116.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $28.66 to $126.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.